Omni Health Announces Upcoming Strategic Acquisitions and Improving its Balance Sheet

MIAMI, FL / ACCESSWIRE / September 27, 2018 / Omni Health, Inc. (OTC PINK: OMHE), a vertically integrated healthcare company dedicated to the development of pharmaceuticals, anti-aging products, and biotech engineering, today announced that it finalizes agreements to acquire 2 privately held companies in the coveted medical technology field and plans to announce the details in the coming weeks.

Company also plans to improve profitability and improve its balance sheet position by discontinuing its pharmacy operations. The proceeds from this discontinued operations will be used to satisfy some of Company’s current liabilities.

”As we are divesting our lower growth pharmacy business, we will be building a strong portfolio by acquiring fast-growing, highly differentiated business in highly coveted medical technology field consistent with the Company’s growth plan announced previously,” said Andrey Soloviev, CEO of Omni Health. ”These acquisitions will be defining moment for our company, and will provide a long-term value for our shareholders. We have made significant progress toward the main strategic goals we have announced previously. These transformation measures will improve the Company’s financial strength and significantly enhance our balance sheet, improving stockholders’ equity and cash flow.”

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.

Contact:

Andrey Soloviev
CEO
ceo@OmniHealth.md

SOURCE: Omni Health, Inc.

ReleaseID: 512831